Table of Contents
Advances in Hepatology
Volume 2014, Article ID 621380, 7 pages
http://dx.doi.org/10.1155/2014/621380
Review Article

Newly Identified Mechanisms of Total Parenteral Nutrition Related Liver Injury

1St. Louis University School of Medicine, Cardinal Glennon Children’s Medical Center, 1465 South Grand Boulevard, St. Louis, MO 63104, USA
2Department of Pediatrics, Saint Louis University, SSM Cardinal Glennon Hospital, 1465 South Grand Boulevard, St. Louis, MO 63104, USA

Received 4 March 2014; Accepted 18 May 2014; Published 25 June 2014

Academic Editor: Sharon DeMorrow

Copyright © 2014 Ajay Kumar Jain and Jeffrey H. Teckman. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. J. Dudrick, D. W. Wilmore, H. M. Vars, and J. E. Rhoads, “Long-term total parenteral nutrition with growth, development, and positive nitrogen balance,” Surgery, vol. 64, no. 1, pp. 134–142, 1968. View at Google Scholar · View at Scopus
  2. S. J. Dudrick, “Early developments and clinical applications of total parenteral nutrition,” Journal of Parenteral and Enteral Nutrition, vol. 27, no. 4, pp. 291–299, 2003. View at Google Scholar · View at Scopus
  3. L. Howard, M. Ament, C. R. Fleming, M. Shike, and E. Steiger, “Current use and clinical outcome of home parenteral and enteral nutrition therapies in the United States,” Gastroenterology, vol. 109, no. 2, pp. 355–365, 1995. View at Publisher · View at Google Scholar · View at Scopus
  4. D. H. Teitelbaum, “Parenteral nutrition-associated cholestasis,” Current Opinion in Pediatrics, vol. 9, no. 3, pp. 270–275, 1997. View at Publisher · View at Google Scholar · View at Scopus
  5. E. R. Briones and F. L. Iber, “Liver and biliary tract changes and injury associated with total parenteral nutrition: pathogenesis and prevention,” Journal of the American College of Nutrition, vol. 14, no. 3, pp. 219–228, 1995. View at Google Scholar · View at Scopus
  6. B. A. Carter and R. J. Shulman, “Mechanisms of disease: update on the molecular etiology and fundamentals of parenteral nutrition associated cholestasis,” Nature Clinical Practice Gastroenterology and Hepatology, vol. 4, no. 5, pp. 277–287, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. V. J. Kumpf, “Parenteral nutrition-associated liver disease in adult and pediatric patients,” Nutrition in Clinical Practice, vol. 21, no. 3, pp. 279–290, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. A. K. Jain, B. Stoll, D. G. Burrin, J. J. Holst, and D. D. Moore, “Enteral bile acid treatment improves parenteral nutrition-related liver disease and intestinal mucosal atrophy in neonatal pigs,” The American Journal of Physiology: Gastrointestinal and Liver Physiology, vol. 302, no. 2, pp. G218–G224, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. D. A. Kelly, “Intestinal failure-associated liver disease: what do we know today?” Gastroenterology, vol. 130, no. 2, pp. S70–S77, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. D. L. Sigalet, “Short bowel syndrome in infants and children: an overview,” Seminars in Pediatric Surgery, vol. 10, no. 2, pp. 49–55, 2001. View at Google Scholar · View at Scopus
  11. P. J. Javid, S. Collier, D. Richardson et al., “The role of enteral nutrition in the reversal of parenteral nutrition-associated liver dysfunction in infants,” Journal of Pediatric Surgery, vol. 40, no. 6, pp. 1015–1018, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. R. A. Drongowski and A. G. Coran, “An analysis of factors contributing to the development of total parenteral nutrition-induced cholestasis,” Journal of Parenteral and Enteral Nutrition, vol. 13, no. 6, pp. 586–589, 1989. View at Google Scholar · View at Scopus
  13. A. Dilsiz, “Total parenteral nutrition-associated cholestasis in surgical neonates,” Turkish Journal of Medical Sciences, vol. 29, pp. 689–692, 1999. View at Google Scholar
  14. C. S. Erickson, A. J. Barlow, J. F. Pierre et al., “Colonic enteric nervous system analysis during parenteral nutrition,” Journal of Surgical Research, vol. 184, no. 1, pp. 132–137, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. A. C. Mosenthal, D. Xu, and E. A. Deitch, “Elemental and intravenous total parenteral nutrition diet-induced gut barrier failure is intestinal site specific and can be prevented by feeding nonfermentable fiber,” Critical Care Medicine, vol. 30, no. 2, pp. 396–402, 2002. View at Google Scholar · View at Scopus
  16. M. Ekelund, M. Ekelund, S. S. Qader, M. Hallén, and E. Ekblad, “Effects of total parenteral nutrition on rat enteric nervous system, intestinal morphology, and motility,” Journal of Surgical Research, vol. 124, no. 2, pp. 187–193, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Niinikoski, B. Stoll, X. Guan et al., “Onset of small intestinal atrophy is associated with reduced intestinal blood flow in TPN-fed neonatal piglets,” Journal of Nutrition, vol. 134, no. 6, pp. 1467–1474, 2004. View at Google Scholar · View at Scopus
  18. M. Miyata, T. Hata, H. Yamakawa, T. Kagawa, K. Yoshinari, and Y. Yamazoe, “Involvement of multiple elements in FXR-mediated transcriptional activation of FGF19,” Journal of Steroid Biochemistry and Molecular Biology, vol. 132, no. 1-2, pp. 41–47, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. F. J. Gonzalez, “Nuclear receptor control of enterohepatic circulation,” Comprehensive Physiology, vol. 2, no. 4, pp. 2811–2828, 2012. View at Publisher · View at Google Scholar
  20. M. Makishima, A. Y. Okamoto, J. J. Repa et al., “Identification of a nuclear receptor for bite acids,” Science, vol. 284, no. 5418, pp. 1362–1365, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. R. G. J. Visschers, M. D. Luyer, F. G. Schaap, S. W. M. Olde Damink, and P. B. Soeters, “The gut-liver axis,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 16, no. 5, pp. 576–581, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Claudel, B. Staels, and F. Kuipers, “The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 10, pp. 2020–2031, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Modica, M. Petruzzelli, E. Bellafante et al., “Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis,” Gastroenterology, vol. 142, no. 2, pp. 355.e4–365.e4, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. S. J. L. B. Zweers, K. A. C. Booij, M. Komuta et al., “The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract,” Hepatology, vol. 55, no. 2, pp. 575–583, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. B. Goodwin, S. A. Jones, R. R. Price et al., “A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis,” Molecular Cell, vol. 6, no. 3, pp. 517–526, 2000. View at Google Scholar · View at Scopus
  26. T. T. Lu, M. Makishima, J. J. Repa et al., “Molecular basis for feedback regulation of bile acid synthesis by nuclear receptos,” Molecular Cell, vol. 6, no. 3, pp. 507–515, 2000. View at Google Scholar · View at Scopus
  27. J. A. Holt, G. Luo, A. N. Billin et al., “Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis,” Genes and Development, vol. 17, no. 13, pp. 1581–1591, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Wang, Y.-K. Lee, D. Bundman et al., “Redundant pathways for negative feedback regulation of bile acid production,” Developmental Cell, vol. 2, no. 6, pp. 721–731, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Inagaki, M. Choi, A. Moschetta et al., “Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis,” Cell Metabolism, vol. 2, no. 4, pp. 217–225, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Lundåsen, C. Gälman, B. Angelin, and M. Rudling, “Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man,” Journal of Internal Medicine, vol. 260, no. 6, pp. 530–536, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. M.-H. Xie, I. Holcomb, B. Deuel et al., “FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4,” Cytokine, vol. 11, no. 10, pp. 729–735, 1999. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Nishimura, Y. Utsunomiya, M. Hoshikawa, H. Ohuchi, and N. Itoh, “Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain,” Biochimica et Biophysica Acta, vol. 1444, no. 1, pp. 148–151, 1999. View at Publisher · View at Google Scholar · View at Scopus
  33. E. Tomlinson, L. Fu, L. John et al., “Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity,” Endocrinology, vol. 143, no. 5, pp. 1741–1747, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. I. Kim, S.-H. Ahn, T. Inagaki et al., “Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine,” Journal of Lipid Research, vol. 48, no. 12, pp. 2664–2672, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Fu, L. M. John, S. H. Adams et al., “Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes,” Endocrinology, vol. 145, no. 6, pp. 2594–2603, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. S. E. Hughes, “Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues,” Journal of Histochemistry and Cytochemistry, vol. 45, no. 7, pp. 1005–1019, 1997. View at Google Scholar · View at Scopus
  37. C. Yu, F. Wang, M. Kan et al., “Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4,” The Journal of Biological Chemistry, vol. 275, no. 20, pp. 15482–15489, 2000. View at Publisher · View at Google Scholar · View at Scopus
  38. X. Huang, C. Yang, Y. Luo, C. Jin, F. Wang, and W. L. McKeehan, “FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet-induced fatty liver,” Diabetes, vol. 56, no. 10, pp. 2501–2510, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. J. E. Heubi, D. A. Wiechmann, V. Creutzinger et al., “Tauroursodeoxycholic acid (TUDCA) in the prevention of total parenteral nutrition-associated liver disease,” Journal of Pediatrics, vol. 141, no. 2, pp. 237–242, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. E. Reihner, I. Bjorkhem, B. Angelin, S. Ewerth, and K. Einarsson, “Bile acid synthesis in humans: regulation of hepatic microsomal cholesterol 7α-hydroxylase activity,” Gastroenterology, vol. 97, no. 6, pp. 1498–1505, 1989. View at Google Scholar · View at Scopus
  41. D. J. Parks, S. G. Blanchard, R. K. Bledsoe et al., “Bile acids: natural ligands for an orphan nuclear receptor,” Science, vol. 284, no. 5418, pp. 1365–1368, 1999. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Lucas, S. R. Bloom, and A. Aynsley Green, “Metabolic and endocrine consequences of depriving preterm infants of enteral nutrition,” Acta Paediatrica Scandinavica, vol. 72, no. 2, pp. 245–249, 1983. View at Google Scholar · View at Scopus
  43. T. Fedorowski, G. Salen, G. S. Tint, and E. Mosbach, “Transformation of chenodeoxycholic acid and ursodeoxycholic acid by human intestinal bacteria,” Gastroenterology, vol. 77, no. 5, pp. 1068–1073, 1979. View at Google Scholar · View at Scopus
  44. C. R. Cole and T. R. Ziegler, “Small bowel bacterial overgrowth: a negative factor in gut adaptation in pediatric SBS,” Current Gastroenterology Reports, vol. 9, no. 6, pp. 456–462, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. S. N. Lichtman, R. B. Sartor, J. Keku, and J. H. Schwab, “Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth,” Gastroenterology, vol. 98, no. 2, pp. 414–423, 1990. View at Google Scholar · View at Scopus
  46. H. R. Freund, M. Muggia-Sullam, R. LaFrance, E. B. Enrione, M. B. Popp, and H. S. Bjornson, “A possible beneficial effect of metronidazole in reducing TPN-associated liver function derangements,” Journal of Surgical Research, vol. 38, no. 4, pp. 356–363, 1985. View at Google Scholar · View at Scopus
  47. J. F. Whiting, R. M. Green, A. B. Rosenbluth, and J. L. Gollan, “Tumor necrosis factor—alpha decreases hepatocyte bile salt uptake and mediates endotoxin-induced cholestasis,” Hepatology, vol. 22, no. 4, part 1, pp. 1273–1278, 1995. View at Google Scholar · View at Scopus
  48. A. A. Nanji and F. H. Anderson, “Cholestasis associated with parenteral nutrition develops more commonly with hematologic malignancy than with inflammatory bowel disease,” Journal of Parenteral and Enteral Nutrition, vol. 8, no. 3, p. 325, 1984. View at Google Scholar · View at Scopus
  49. H. Fouin-Fortunet, L. Le Quernec, S. Erlinger, E. Lerebours, and R. Colin, “Hepatic alterations during total parenteral nutrition in patients with inflammatory bowel disease: a possible consequence of lithocholate toxicity,” Gastroenterology, vol. 82, no. 5, part 1, pp. 932–937, 1982. View at Google Scholar · View at Scopus
  50. Y. J. Zheng, Y. K. Tam, and R. T. Coutts, “Endotoxin and cytokine released during parenteral nutrition,” Journal of Parenteral and Enteral Nutrition, vol. 28, no. 3, pp. 163–168, 2004. View at Google Scholar · View at Scopus
  51. E. H. Forrest, K. A. Oien, S. Dickson, D. Galloway, and P. R. Mills, “Improvement in cholestasis associated with total parenteral nutrition after treatment with an antibody against tumour necrosis factor alpha,” Liver, vol. 22, no. 4, pp. 317–320, 2002. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Trauner, M. Arrese, H. Lee, J. L. Boyer, and S. J. Karpen, “Endotoxin downregulates rat hepatic ntcp gene expression via decreased activity of critical transcription factors,” Journal of Clinical Investigation, vol. 101, no. 10, pp. 2092–2100, 1998. View at Google Scholar · View at Scopus
  53. M. Hojo, N. Sano, and H. Takikawa, “Effects of lipopolysaccharide on the biliary excretion of bile acids and organic anions in rats,” Journal of Gastroenterology and Hepatology, vol. 18, no. 7, pp. 815–821, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. R. Ghose, T. L. Zimmerman, S. Thevananther, and S. J. Karpen, “Endotoxin leads to rapid subcellular re-localization of hepatic RXRα: a novel mechanism for reduced hepatic gene expression in inflammation,” Nuclear Receptor, vol. 2, article 4, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. T. Inagaki, A. Moschetta, Y.-K. Lee et al., “Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 10, pp. 3920–3925, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. R. M. Gadaleta, K. J. Van Erpecum, B. Oldenburg et al., “Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease,” Gut, vol. 60, no. 4, pp. 463–472, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. B. A. Carter, O. A. Taylor, D. R. Prendergast et al., “Stigmasterol, a soy lipid-derived phytosterol, is an antagonist of the bile acid nuclear receptor FXR,” Pediatric Research, vol. 62, no. 3, pp. 301–306, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. J. Fuchs, E. M. Fallon, K. M. Gura, and M. Puder, “Use of an omega-3 fatty acid-based emulsion in the treatment of parenteral nutrition-induced cholestasis in patients with microvillous inclusion disease,” Journal of Pediatric Surgery, vol. 46, no. 12, pp. 2376–2382, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. H. E. Lilja, Y. Finkel, M. Paulsson, and S. Lucas, “Prevention and reversal of intestinal failure-associated liver disease in premature infants with short bowel syndrome using intravenous fish oil in combination with omega-6/9 lipid emulsions,” Journal of Pediatric Surgery, vol. 46, no. 7, pp. 1361–1367, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. R. S. Venick and K. Calkins, “The impact of intravenous fish oil emulsions on pediatric intestinal failure-associated liver disease,” Current Opinion in Organ Transplantation, vol. 16, no. 3, pp. 306–311, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. Y. H. Yu, E. C. Lin, S. C. Wu et al., “Docosahexaenoic acid regulates adipogenic genes in myoblasts via porcine peroxisome proliferator-activated receptor {gamma},” Journal of Animal Science, vol. 86, no. 12, pp. 3385–3392, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. G. L. Størvold, K. G. Fleten, C. G. Olsen, T. Follestad, H. E. Krokan, and S. A. Schønberg, “Docosahexaenoic acid activates some SREBP-2 targets Independent of cholesterol and ER stress in SW620 colon cancer cells,” Lipids, vol. 44, no. 8, pp. 673–683, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. G. Howell III, X. Deng, C. Yellaturu et al., “N-3 polyunsaturated fatty acids suppress insulin-induced SREBP-1c transcription via reduced trans-activating capacity of LXRα,” Biochimica et Biophysica Acta, vol. 1791, no. 12, pp. 1190–1196, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. N. Tanaka, X. Zhang, E. Sugiyama et al., “Eicosapentaenoic acid improves hepatic steatosis independent of PPARα activation through inhibition of SREBP-1 maturation in mice,” Biochemical Pharmacology, vol. 80, no. 10, pp. 1601–1612, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. A. Zhao, J. Yu, J.-L. Lew, L. Huang, S. D. Wright, and J. Cui, “Polyunsaturated fatty acids are FXR ligands and differentially regulate expression of FXR targets,” DNA and Cell Biology, vol. 23, no. 8, pp. 519–526, 2004. View at Publisher · View at Google Scholar · View at Scopus
  66. T. Yoshikawa, H. Shimano, N. Yahagi et al., “Polyunsaturated fatty acids suppress sterol regulatory element-binding protein 1c promoter activity by inhibition of liver X receptor (LXR) binding to LXR response elements,” Journal of Biological Chemistry, vol. 277, no. 3, pp. 1705–1711, 2002. View at Publisher · View at Google Scholar · View at Scopus